Imagine a future where your inhaler not only tracks your usage but also alerts your doctor if you’re at risk of an asthma attack. This is just one example of how the Internet of Medical Things (IoMT) is transforming patient care. But the digital health revolution is about much more than IoMT. From artificial intelligence (AI) to blockchain, digital health technologies are rapidly changing how the pharmaceutical industry operates, creating both opportunities and challenges across the entire pharmaceutical lifecycle.
Digital health encompasses a range of technologies designed to improve health outcomes, streamline processes, and enhance the patient experience. At its core, this revolution is reshaping drug development, clinical trials, and patient care. As these technologies evolve, pharmaceutical companies must adapt—not only by adopting new tools but by addressing workforce training, operational adjustments, and regulatory alignment to fully unlock their potential.¹
To thrive in this era of rapid innovation, pharmaceutical companies must embrace digital health technologies and navigate the complexities they bring. In the sections below, we’ll explore how these tools are driving transformation in R&D, patient care, and more, while offering actionable strategies for staying ahead in the digital age.
Blockchain: Securing supply chains and enabling transparency
Blockchain technology is now essential to ensuring drug traceability and supply chain efficiency. Its decentralized and immutable ledger system that securely records transactions and information across a computer network provides a secure framework for tracking pharmaceuticals from production to patient delivery.
The growing role of blockchain in the pharmaceutical industry is evident in market projections. The global market for blockchain in the pharmaceutical market was valued at $1.2 trillion in 2023, based on growing at a compound annual growth rate (CAGR) of 17.2% from 2024 to 2030.²
Real-world examples illustrate its impact³˒⁴˒⁵:
Merck partners with SAP to employ blockchain for preventing counterfeit drugs from entering the supply chain while improving operational transparency.
PharmaLedger, a collaboration of 12 pharmaceutical companies, integrates blockchain with IoT (Internet of Things) sensors to monitor temperature during transportation and storage of sensitive medicines, like vaccines. This ensures real-time tracking of drug provenance and quality.
Beyond supply chain management, blockchain is increasingly used in clinical trials to ensure data integrity.⁶
By preventing interference of trial results or patient records, blockchain fosters trust among regulators, sponsors, and healthcare providers. Its role in maintaining transparency is vital as clinical trials grow more decentralized and reliant on digital tools.
Building on the secure data foundation blockchain provides, the industry is now leveraging the power of AI and machine learning to drive further advancements. These technologies enable faster and more accurate analysis of complex datasets, leading to breakthroughs in drug discovery and accelerating pharmaceutical innovation.⁷
AI and Machine Learning: Accelerating drug development
AI and Machine Learning (ML) are fundamentally transforming the pharmaceutical industry, permeating every aspect of the drug development lifecycle. From transforming drug discovery to optimizing clinical trials and enhancing manufacturing processes, AI/ML is not just improving existing workflows but also unlocking entirely new possibilities.
While its applications are vast and rapidly expanding, there are several areas where AI/ML is currently making a significant impact within the pharmaceutical product development lifecycle, including:
Drug Discovery: AI analyzes large biological datasets to identify disease-associated targets, predict drug interactions, and accelerate the discovery of novel compounds. This streamlines the early stages of drug development, cutting down on time and resources required to bring potential treatments to market.⁸
Clinical Trials: ML-powered predictive models optimize trial designs by identifying ideal participants and forecasting treatment outcomes. AI-driven adaptive trial designs adjust patient allocation in real-time, improving the efficiency and accuracy of trials while minimizing costs.
Manufacturing and Quality Control: AI and ML also play a crucial role in pharmaceutical manufacturing, enhancing production efficiency and ensuring consistent product quality. Predictive algorithms can forecast production needs, optimize supply chain operations, and reduce waste, helping companies maintain higher standards and improve cost-effectiveness.
As AI/ML technologies advance, incorporating innovations like deep learning and neural networks, their impact expands across the entire pharmaceutical product development lifecycle, improving efficiencies, reducing costs, and accelerating the development of new therapies. These innovations are helping the industry keep pace with the growing demand for faster, more effective drug development.
Building on this enhanced model, IoMT is emerging as another transformative force. By providing real-time data collection and monitoring, IoMT devices are further revolutionizing patient care and clinical trials, working hand-in-hand with AI/ML to drive better outcomes.
Internet of Medical Things (IoMT): Transforming patient monitoring
IoMT devices are reshaping patient care through real-time data collection and monitoring. From wearable sensors to smart pill dispensers, these devices provide actionable insights into patient adherence and drug efficacy, enabling healthcare providers to make informed decisions that improve outcomes.
A testament to the growing adoption of IoMT, the remote patient monitoring (RPM) market is rapidly expanding, with the number of RPM patients in the U.S. rising from 23 million in 2020 to 30 million in 2024, and projections indicate this number will reach 70.6 million by the end of 2025.⁹
The integration of IoMT devices in clinical settings is revolutionizing patient care by enabling real-time monitoring and enabling continuous monitoring personalized interventions. A notable example is Novartis' collaboration with Qualcomm, where biometric data collected through mobile apps is used to remotely monitor lung disease interventions, improving patient outcomes by providing timely insights. The app for the Breezhaler™ inhaler helps patients and healthcare providers track inhaler usage in near real-time, thus preventing overuse or misuse that could lead to unnecessary waste. This continuous monitoring not only improves patient adherence but also leads to better clinical outcomes. In fact, studies have shown that remote patient monitoring through IoMT devices can reduce hospital readmission rates by up to 25%.⁹˒¹⁰
This shift toward continuous monitoring and data-driven patient care isn’t limited to patient interactions alone—it's also reshaping broader aspects of the pharmaceutical and healthcare ecosystem. Beyond clinical settings, IoMT plays a critical role in manufacturing optimization. Smart sensors, much like those used for patient monitoring, help reduce waste, offer more accurate data on usage patterns, and improve quality control. These innovations enable manufacturers and suppliers to better plan production and distribution, minimizing overproduction of drugs and medical devices.
In addition, IoMT is also having a transformative effect on clinical trials. By decentralizing data collection, IoMT allows continuous monitoring of participants outside traditional study sites, reducing logistical burdens while enhancing the accuracy of trial data. Studies show that IoMT implementation can reduce clinical trial costs by 25-30%, helping organizations run trials more efficiently.⁹
As AI/ML continue to advance, IoMT devices, coupled with these technologies, can create even more immersive and interactive experiences, enhancing data interpretation and communication for better patient outcomes and faster drug development.
Augmented Reality (AR): Enhancing education and engagement
Augmented Reality (AR) is one such technology, offering innovative ways to enhance training, education, and patient engagement by making complex information more accessible and understandable. By overlaying digital information on the physical world, AR helps simplify intricate medical concepts, improving both learning and patient outcomes.
In training, AR enables medical simulations where 3D organs are projected during practice surgeries. This helps trainees visualize organ function in real time, improving understanding and skills without risk to real patients. Additionally, AR is being used for device training, providing an immersive environment for trial and error.
AR also enhances patient education by offering interactive visualizations of health conditions and treatments. For example, AR apps can demonstrate how medications affect the body, empowering patients to better understand and manage their health.
As AR evolves, it holds the potential to revolutionize medical training and patient care. When combined with other technologies like AI and IoMT, AR is poised to further enhance how healthcare professionals and patients interact with medical information, improving outcomes and efficiency across the industry.¹¹
Connectivity and data integrity
The integration of blockchain with IoMT and AR ensures seamless connectivity across the pharmaceutical ecosystem, providing stakeholders with unprecedented access to vast amounts of data. As data generation and accessibility increase exponentially, maintaining data integrity becomes paramount. Robust mechanisms to safeguard data are essential for ensuring trust in decentralized clinical trials, regulatory compliance, and the effectiveness of pharmaceutical innovations. Without these mechanisms, the reliability of these innovations could be compromised, affecting patient outcomes and regulatory approval.¹²
However, the increasing volume of IoMT data raises concerns about its effectiveness and clinical impact. A recent study showed that while 93% of patients expressed satisfaction, 97% found the technology feasible, and 88% accepted its use, only 27% (4/15) of trials showed significant improvements in health-related quality of life. These findings underscore the importance of examining the broader impact of IoMT data in clinical practice.¹³
Meanwhile, the role of AR contributes to the increase in data volume by enhancing patient engagement through interactive wearables and medication reminders. These devices capture novel clinical features that traditional study visits may miss. Blockchain technology helps secure these records against alteration, while also providing transparent access for regulators evaluating trial outcomes.
In the face of these technological advancements, ensuring data integrity and security in these innovative applications of AR is not just a matter of patient safety and trust—its critical for navigating the evolving regulatory landscape that governs digital health technologies.
Navigating regulatory challenges
As digital health technologies continue to evolve and generate increasingly complex data, regulatory frameworks must adapt to ensure data integrity and security. Currently, guidance for these emerging technologies remains limited, as it struggles to keep up with the novelty of these tools. However, regulatory bodies like the FDA are actively developing updated guidelines for digital health technologies, including AI/ML-based software as medical devices (SaMD).¹⁴
SaMD examples include mobile health applications, diagnostic algorithms, and software that provides therapeutic recommendations. These software products are subject to regulatory oversight to ensure they meet safety and effectiveness standards. The FDA has issued draft guidance to support the development and marketing of AI-enabled medical devices throughout their lifecycle, addressing aspects like continuous learning and adaptation post-market.
As digital health technologies like AR, AI, IoMT, and SaMD continue to be integrated into clinical trials and product development pipelines, regulatory bodies are refining their frameworks to address specific challenges related to each of these tools. For instance, AR applications in healthcare—whether for training, patient engagement, or clinical practice—pose unique regulatory questions around data privacy, safety, and efficacy, which must be addressed as these tools evolve.
Ensuring data integrity and security in these innovative applications is critical for patient safety and trust and navigating the evolving regulatory landscape that governs digital health technologies. As more guidance emerges, it will shape how these tools are used in clinical settings. Pharmaceutical companies must remain agile in adapting their strategies to align with evolving regulations while ensuring compliance. Additionally, to effectively navigate this complex regulatory environment and fully leverage digital technologies, it's essential to invest in comprehensive training programs that equip employees with the necessary skills and knowledge.
The training imperative
The integration of digital technologies like AI, blockchain, IoMT, and AR is transforming the pharmaceutical industry, creating both opportunities and regulatory challenges. To effectively navigate this evolving landscape, organizations must prioritize specialized training programs that equip employees with the necessary skills and knowledge. This training should encompass technical expertise, regulatory awareness, effective communication, and patient-centric engagement, enabling employees across various roles to fully leverage these tools and drive innovation.
Pharmaceutical representatives must be well-versed not only in understanding trial results but also in how advanced technologies contributed to those results. For instance, if AI was used for adaptive trial design or participant selection, reps should be able to explain how this improved efficiency or enhanced data quality. Similarly, if IoMT devices were used for remote monitoring during a trial, reps need to articulate how this technology provided continuous insights into patient adherence or safety metrics.
Beyond technical expertise, representatives also must stay informed about the evolving regulatory landscape, including FDA guidelines on SaMD or AI-based solutions. This ensures that reps can discuss trial outcomes confidently and in a way that aligns with the most current standards and practices.
Equally important is the ability to communicate complex concepts clearly. Representatives must be able to translate technical details into accessible language for HCPs, who may not be familiar with emerging technologies. Effective communication ensures that HCPs understand the impact of these tools on patient care, safety, and trial efficiency, even if without technical expertise.¹⁵
Finally, training should emphasize how new technologies like wearables and augmented reality tools can enhance patient education and engagement. Employees should be equipped to explain how these tools improve patient adherence, provide real-time feedback, and ultimately lead to better patient outcomes. By keeping their knowledge up-to-date, reps can effectively communicate the value of these innovations to both HCPs and patients.
Conclusion: A connected future
The convergence of blockchain, AI/ML, IoMT, and AR is reshaping the pharmaceutical industry, driving innovation across R&D, clinical trials, manufacturing, and patient care. These interconnected technologies offer immense potential to enhance efficiency, improve patient outcomes, and increase transparency.
As these digital health solutions continue to become embedded into every facet of the pharmaceutical lifecycle, the question remains: How is your organization preparing its workforce to fully harness the potential of these advancements?
By prioritizing comprehensive training programs, investing in the right skills, and staying agile in the face of evolving regulations, organizations can ensure their teams will be prepared to navigate this fast-paced digital transformation. Ensuring your workforce is equipped with the knowledge to communicate effectively with healthcare providers, regulatory bodies, and patients will be key to leveraging the full power of digital health technologies.
The success of this revolution hinges on the people who implement these tools—so the question isn’t just about keeping pace with change, but how will your organization lead the way in shaping the future of pharmaceutical innovation? To truly harness the power of blockchain, AI/ML, IoMT, and AR, now is the time to invest in training. Let’s build a workforce ready to lead in digital health.
References:
Eastburn J, Fowkes J, K K. Digital transformation: health systems' investment priorities. McKinsey & Company Healthcare. 2024.
Pharmiweb. Blockchain in pharmaceutical market size report 2023. 2025.
EMD Group. Blockchain: A smarter and more connected world. EMD Group. 2025.
Uddin M, Salah K, Jayaram R, Pesic S, S E. Blockchain for drug traceability: Architectures and open challenges. SageJournals. 2021.
Ledger Insights. Blockchain consortium PharmaLedger: Use cases in pharma. Ledger Insights. 2023.
RY Medi. Transforming clinical trials with blockchain technology: innovations and challenges in 2024. Updated 2024. Accessed April 10, 2025.
Nanotronics. 8 innovative applications of AI in pharmaceutical industry. Updated 2025.
Vivisen. Artificial intellgience in the pharma industry. Updated 2025.
Healtharc. Key remote patient monitoring statistics every practice should know. Updated 2024. Accessed April 10, 2025.
Novartis. Novartis Pharmaceuticals collaborates with Qualcomm on digital innovation for Breezhaler™ inhaler device to treat COPD. Updated 2023.
Koniukh A. How is animation used in the medical field? Updated 2024. Accessed April 10, 2025.
Pokharel BP, Kshetri N, Sharma SR, S P. blockHealthSecure: Integrating clockchain and cybersecurity in post-pandemic healthcare systems. MDPI. 2025.
Pogorzelska K, S. C. Patient satisfaction with telemedicine during the COVID-19 pandemic—A systematic review. International Journal of Environmental Research and Public Health. 2022.
U.S. Food and Drug Administration. Transparency of machine learning-enabled medicaldevices: guiding principles. Updated 2021.
Mantel-Teeuwisse AK, Meilianti S, Khatri B, et al. Digital health in pharmacy education: preparedness and responsiveness of pharmacy programmes. MDPI. 2021.
